C
Coherus BioSciences Inc (CHRS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$0.51
-0.02 (-3.73%)
Market Cap: $81.21M
Last updated: Nov 17, 2026 at 11:04 AM ET
Coherus BioSciences Inc (CHRS) Valuation Multiples
Coherus BioSciences (CHRS) trades at 1.5x sales and 3.1x book value. Its P/S of 1.5x is below its 5-year median of 2.9x. Its forward P/E is 41.1x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 41.1x |
| Price to sales | 1.5x |
| Price to book | 3.1x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/S is 55.9% below 3.4x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 1.5x | 2.9x | 3.4x |
Valuation History
Over the 9 of the 10 year ends shown that have a P/S, its P/S ranged from 1.2x in 2023 to 153.9x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $1.42 | N/A | 4.0x | 2.8x |
| 2024 | $1.38 | N/A | 6.0x | N/A |
| 2023 | $3.33 | N/A | 1.2x | N/A |
| 2022 | $7.92 | N/A | 2.9x | N/A |
| 2021 | $15.96 | N/A | 3.7x | 12.5x |
| 2020 | $17.38 | 10.7x | 2.7x | 5.4x |
| 2019 | $18.01 | 14.8x | 3.7x | 13.4x |
| 2018 | $9.05 | N/A | N/A | N/A |
| 2017 | $8.80 | N/A | 153.9x | 16.8x |
| 2016 | $28.15 | N/A | 6.4x | 64.5x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CHRS
What is CHRS's forward P/E ratio?
Coherus BioSciences has a forward P/E ratio of 41.1x.
Is CHRS stock overvalued?
GNG's valuation label for CHRS is Undervalued.
What is CHRS's price to sales ratio?
Coherus BioSciences has a price to sales ratio of 1.5x.
CHRS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors